Safety and Efficacy of Oshadi D and Oshadi R in Basal Cell Carcinoma Patients Prior to Tumor Excision a Phase 2 Study
This study is single-arm, none randomized, open label, two-dose-cohorts, single center clinical trial for evaluation of the safety and efficacy of Oshadi D and Oshadi R in patients with BCC. Patients will receive Oshadi D and Oshadi R for 60 -90 days until the planned surgical excision of the lesion.
BCC
DRUG: Oshadi D & Oshadi R
Adverse events and serious adverse events occurence, treatment end (day 60 or 90)
The primary efficacy endpoint of this study is Overall Response Rate (ORR), treatment end (day 60 or 90)
To estimate the duration of treatment to achieve response, To estimate the duration of treatment needed to achieve response, 9 months
This study is single-arm, none randomized, open label, two-dose-cohorts, single center clinical trial for evaluation of the safety and efficacy of Oshadi D and Oshadi R in patients with BCC. Patients will receive Oshadi D and Oshadi R for 60 -90 days until the planned surgical excision of the lesion.